Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification
NCT ID: NCT02864563
Last Updated: 2023-12-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
560 participants
INTERVENTIONAL
2008-10-04
2023-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This protocol deals with a prospective analysis of the genomic profile established by CGH-array on the tumor samples obtained at the diagnosis of all the patients with NB in France, to obtain genomic profiles and being able to determine their prognostic impact in the various protocols of treatment. The objective of this study will be a better therapeutic stratification in the future trials, studies or protocols of treatment.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Frozen tumor sample (cell content ≥60%) must be sent for genomic profile determination by CGH-array,
* Blood sample at diagnosis must be sent to evaluate MYCN amplification in plasma,
* In case of NB with a MYCN amplification, blood sample during treatment and follow-up must be sent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prospective cohort
Experimental arm, prospective cohort
Blood sampling
* Blood sample at diagnosis to evaluate MYCN amplification in plasma.
* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sampling
* Blood sample at diagnosis to evaluate MYCN amplification in plasma.
* In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age \< 18 years
3. Availability of tumoral sample obtained at diagnosis, prior chemotherapy with tumor cell content ≥ 60%
4. Inclusion in 4 months following the diagnosis
5. All patients treated in French centers (SFCE) for Neuroblastic tumour, including those participate in national or international protocols.
7\. Written informed consent 8. Patients with French Social Security in compliance with the French law relating to biomedical research.
Exclusion Criteria
2. Refusal of the parents or the legal representatives
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Curie
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gudrun Shleiermacher, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Institut Curie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Nord Amiens
Amiens, , France
Chu Angers
Angers, , France
Chr R.Pellegrin
Bordeaux, , France
CHU MORVAN Brest
Brest, , France
CHR CAEN
Caen, , France
Chu Bocage
Dijon, , France
Chu Grenoble
Grenoble, , France
Chu Lille
Lille, , France
Hopital de La Mere Et de L'Enfant Limoges
Limoges, , France
Centre Leon Berard
Lyon, , France
Hopital D'Enfants de La Timone
Marseille, , France
Hopital Arnaud de Villeneuve
Montpellier, , France
CHR MONCOUSU Nantes
Nantes, , France
CHU Nice Hôpital L'Archet 2
Nice, , France
Institut Curie
Paris, , France
Hôpital Armand TROUSSEAU
Paris, , France
Hôpital Jean Bernard de la Milétrie
Poitiers, , France
Höpital Americain Reims
Reims, , France
CHR Hôpital Sud Rennes
Rennes, , France
Hôpital Charles Nicolle ROUEN
Rouen, , France
Chr Felix Guyon
Saint-Denis, , France
CHU SAINT-ETIENNE Hôpital Nord
Saint-Priest-en-Jarez, , France
Hôpital Hautepierre Strasbourg
Strasbourg, , France
Hôpital des Enfants Toulouse
Toulouse, , France
CHU TOURS Hôpital Clocheville
Tours, , France
Hopital Des Enfants Nancy
Vandœuvre-lès-Nancy, , France
Gustave Roussy
Villejuif, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IC 2007-09
Identifier Type: -
Identifier Source: org_study_id